Effects of handling and storage of blood on the stability of hepatitis C virus RNA: implications for NAT testing in transfusion practice

Vox Sang. 2000;78(3):137-42. doi: 10.1159/000031171.

Abstract

Background and objectives: To determine the stability of hepatitis C virus (HCV) RNA during transport and storage of blood samples from donors, prior to screening for HCV by nucleic acid amplification technology.

Materials and methods: Various blood and plasma sample types were stored for up to 120 h at different temperatures and the HCV RNA level was measured using an in house quantitative reverse transcription-polymerase chain reaction.

Results: No decline in HCV RNA level was observed after 72 h of storage of whole blood at 4 degrees C in EDTA tubes (Greiner) and Plasma Preparation Tubes (PPT; Becton Dickinson), while insignificant declines of 0.2 log10 and 0. 25 log10 occurred at 25 degrees C after 72 h in the EDTA tubes and PPT tubes, respectively. When whole blood was stored with mixed anticoagulants CPDA-1 and EDTA for up to 120 h, no decline in HCV RNA level was observed at 4 degrees C and 25 degrees C, while a significant decline of 0.37 log10 occurred at 37 degrees C after 120 h. The temperature during transportation was investigated with a 12-hour period at 25 degrees C and 37 degrees C before storage at 4 degrees C for 108 h. Neither temperature resulted in any loss of HCV RNA in comparison with 120 h of storage at 4 degrees C.

Conclusion: Whole blood anticoagulated with EDTA or CPDA-1/EDTA may be stored at up to 25 degrees C (room temperature) for up to 5 days without any significant loss in plasma HCV RNA level.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / pharmacology
  • Anticoagulants / pharmacology
  • Blood Preservation / adverse effects*
  • Blood Preservation / standards
  • Blood Transfusion
  • Chelating Agents / pharmacology
  • Citrates / pharmacology
  • Cryoprotective Agents / pharmacology
  • Edetic Acid / pharmacology
  • England
  • Gene Amplification
  • Glucose / pharmacology
  • Hepacivirus / genetics*
  • Humans
  • Kinetics
  • Mass Screening
  • Phosphates / pharmacology
  • Plasma / virology
  • Product Packaging
  • RNA, Viral / blood*
  • RNA, Viral / drug effects
  • Reverse Transcriptase Polymerase Chain Reaction
  • Specimen Handling / standards*
  • Temperature
  • Time Factors

Substances

  • Anticoagulants
  • CPDA solutions
  • Chelating Agents
  • Citrates
  • Cryoprotective Agents
  • Phosphates
  • RNA, Viral
  • Edetic Acid
  • Glucose
  • Adenine